SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-015996
Filing Date
2023-05-05
Accepted
2023-05-05 08:16:23
Documents
15
Period of Report
2023-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20230505.htm   iXBRL 8-K 39756
2 EX-99.1 ovid2023q1exhibit991.htm EX-99.1 58036
7 img34400995_0a.jpg GRAPHIC 17099
  Complete submission text file 0001628280-23-015996.txt   285333

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20230505.xsd EX-101.SCH 2150
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20230505_def.xml EX-101.DEF 2889
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20230505_lab.xml EX-101.LAB 26893
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20230505_pre.xml EX-101.PRE 14674
9 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20230505_htm.xml XML 12339
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 23891390
SIC: 2834 Pharmaceutical Preparations